The past is gone. I look for the future. All of the treatments that have been developed can be used in Canine/Feline applications. This treatment approach of gene silencing and beefing up the cells into super cells is just beginning. 1 of 3 dogs die of cancer. The market is worth multi billions in the U.S. World wide is billions. With the current O/S 0f 2.4 billion and pps of .0002 that is a market cap of 480,000. Remember Dr Koos has 75 million, or 3 %, other staff have 75 million, or 3 %. I have 1 %, many others on this board have 1-3 %. The float has slowly been absorbed. News will send this soaring back to a penny in 2015. Don't forget the company is developing COPD treatments using their approach. imo glta ENTB
With Koos holding 75 million, staff holding 75 million, and longs holding at least 1 % (like me) A lot of folks are confident.
Based on 2,405,570, 642 shares issued and outstanding as of November 21, 2014
Title of Class Name and Address of Beneficial Owner
Amount and Nature
of Beneficial Owner
Percent of Class
Common
David R. Koos*
C/o Entest Bio Medical Inc., Inc
4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942
75,000,000 3.1%
Common All Officers and Directors As a Group 75,000,000 3.1%
*Includes 10,000,000 common shares owned by Bio-Matrix Scientific Group, Inc. (David Koos is CEO, President and Chairman of Bio-Matrix Scientific Group, Inc.).
.
Based on 4,201,397 shares issued and outstanding as of November 21, 2014
